SOAT1 and asthma: The dysregulation of the JAK/STAT pathway is involved in many diseases, including autoimmune diseases, asthma, diabetes, and cancers, suggesting that the laccaic acids could be lead compounds for a novel inhibitor that targets the JAK2-STAT1-IRF1 pathway for those diseases.